ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like Merck KGaA, Pfizer's Lung Cancer Drug Flunks Late-Stage Trial February 15, 2018 Biogen To Present Data At July 13, 2017 Providence Medical Technology Announces Publication Of Two New Studies Supporting Tissue-Sparing Posterior Cervical Fusion July 9, 2017
Providence Medical Technology Announces Publication Of Two New Studies Supporting Tissue-Sparing Posterior Cervical Fusion July 9, 2017
